This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AAV Vector (Editas/Adverum)
Drug Names(s): Next-Generation Adeno-Associated Viral (AAV) Vector
Description: Adverum and Editas are using Adverum’s next-generation adeno-associated viral (AAV) vectors with Editas’ leading genome editing technologies to create a series of novel therapies.
Adverum and Editas
In August 2016, Adverum Biotechnologies and Editas Medicine announced a collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. This collaboration brings together Adverums next-generation adeno-associated viral (AAV) vectors for use with Editas leading genome editing technologies to create a series of novel therapies for debilitating eye diseases that have poor therapeutic options.
Under the terms of the agreement, Editas will pay Adverum an upfront fee of $1 million to evaluate Adverum next-generation vectors for use in clinical development. Editas will support all preclinical activities related to this collaboration, with a portion of the upfront fee to be credited against this funding obligation. In addition, Editas will also pay an additional option exercise fee of $1 million for an exclusive license to Adverums next-generation AAV vectors for use in each indication chosen as part of...See full deal structure in Biomedtracker
Partners: Adverum Biotechnologies, Inc.
AAV Vector (Editas/Adverum) News
Additional information available to subscribers only: